

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

13587.286

APPLICATION NO.

09/523,102

APPLICANTS

SI, et al.

FILING DATE

March 10, 2000

GROUP

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1					
	AB1					
	AC1					
	AD1					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION Yes No
	AE1	EP 0312208	09/1988	EP		
	AF1	WO 9529696 A1	11/1995	WO		
	AG1	WO 9603985 A1	02/1996	WO		
	AH1	WO 9741844 A1	11/1997	WO		
	AI1	WO 9810758 A1	03/1998	WO		
	AJ1	WO 9913909 A1	03/1999	WO		
	AK1	WO 9945929 A1	09/1999	WO		
	AL1	WO 0007565 A2	02/2000	WO		
	AM1	WO 0007565 A3	02/2000	WO		
	AN1	EP 1040837 A2	10/2000	EP		
	AO1					
	AP1					

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AQ1	Baraldi, et al., <i>Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrola [2.1-c][1.4]b benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers</i> , Journal of Medical Chemistry 42(25): 5131-41 (1999).
	AR1	Bayless, et al., <i>RGD-Dependent Vacuolation and Lumen Formation Observed during Endothelial Cell Morphogenesis in Three-Dimensional Fibrin Matrices Involves the $\alpha_3\beta_3$ and $\alpha_5\beta_1$ Integrins</i> , American Journal of Pathology 156(5): 1673-83 (2000).
	AS1	Bevilacqua, et al., <i>Recent Contributions to Knowledge of the Mechanism of Action of Nimesulide</i> , Drugs 46 Suppl. 1: 40-47 (1993).
	AT1	Bigg, et al., <i>Mechanisms of induction of human tissue inhibitor of metalloproteinases-1 (TIMP-1) gene expression by all-trans retinoic acid in combination with basic fibroblast growth factor</i> , European Journal of Biochemistry 267(13): 4150-56 (2000).
	AU1	Binetruy-Tournaire, et al., <i>Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis</i> , EMBO J. 19(7): 1525-33 (2000).
	AV1	Campbell, et al., <i>Malonyl aa-Mercaptoketones and a-Mercaptoalcohols, A New Class of Matrix Metalloproteinase Inhibitors</i> , Bioorganic Medical Chemistry Letters 8(10): 1157-62 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

13587.286

APPLICATION NO.

09/523,102

APPLICANTS

SI, et al.

FILING DATE

March 10, 2000

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AW2					
	AX2					
	AY2					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION Yes No
	AZ2					
	BA2					
	BB2					


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

S	BC2		Cherney, et al., <i>Macrocyclic Hydrozamate Inhibitors of Matrix Metalloproteinases and TNF-α Production</i> , Bioorganic Medical Chemistry Letters 9(9): 1279-84 (1999).
S	BD2		Colombo, S., et al., "An Eye Drop Form of an Extracellular Proteinase Inhibitor Prevents Retinal Neovascularization in an Animal Model," Biosciences Information Service cited as XP002183948 on the International Search Report dated March 15, 2000.
S	BE2		Colorado, et al., <i>Anti-angiogenic Cures From Vascular Basement Membrane Collagen</i> , Cancer Research 69(9): 2520-26 (2000).
S	BF2		Coors, et al., <i>The Investigative Ophthalmology & Visual Sciences</i> 40(4): S231 (1999).
S	BG2		Dark, et al., <i>Combretastatin A-4, an Agent that Displays Patent and Selective Toxicity toward Tumor Vasculature</i> , Cancer Research 57 (10): 1829-34 (1997).
S	BH2		Fairbrother, et al., <i>Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site</i> , Biochemistry 37(51): 17754-64 (1998).
S	BI2		Fife, et al., <i>Effects of tetracyclines on angiogenesis in vitro</i> , Cancer Letters 153(1-2): 75-8 (2000).
S	BJ2		Fini, et al., <i>An Inhibitor of the Matrix Metalloproteinase Synthesized</i> , Invest. Ophthalmol. Vis. Sci. 32(11): 2997-3001 (1991).
S	BK2		Floege, et al., <i>Novel Approach to Specific Growth Factor Inhibition in Vivo</i> , American Journal of Pathology 154(1): 169-79 (1999).
S	BL2		Gilbertson-Beadling, et al., <i>The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism</i> , Cancer Chemother. Pharmacol. 36(5): 418-24 (1995).
S	BM2		Greenwald, et al., <i>Tetracyclines Suppress Matrix Metalloproteinase Activity in Adjuvant Arthritis and in Combination with Flurbiprofen, Ameliorate Bone Damage</i> , Journal of Rheumatology 19(6): 927-38 (1992).
S	BN2		Griscelli, et al., <i>Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest</i> , Proceedings of the National Academy of Sciences U.S.A., 95(11): 6367-72 (1998).
S	BO2		Hanessian, et al., <i>Picking The S₁, S_i and S₂ Pockets of Matrix Metalloproteinases, A Niche for Potent Acyclic Sulfonamide Inhibitors</i> , Bioorganic Medical Chemistry Letters 9(12): 1691-96 (1999).
S	BP2		Hanglow, et al., <i>Peptides based on the conserved prodomain sequence of matrix metalloproteinases inhibit human stromelysin and collagenase</i> , Agents Actions 39 Spec. No.: C148-50 (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

	FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 13587.286	APPLICATION NO. 09/523,102
			APPLICANTS SI, et al.	SEP 27 2002
			FILING DATE March 10, 2000	GROUP TECH CENTER 1600/2900














U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	BQ3					
	BR3					
	BS3					


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION Yes No
	BT3					
	BU3					
	BV3					

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	BW3	International Search Report, Application No. PCT/US01/07171, filed March 7, 2001.
	BX3	Investigative Ophthalmology Visual Science, Vol. 41, No. 4, S640 (2000).
	BY3	Jacobson, et al., <i>Structure-Based Design and Synthesis of a Series of Hydroxamic Acids With a Quaternary-Hydroxy Group in P1 As Inhibitors of Matrix Metalloproteinases</i> , Bioorganic Medical Chemistry Letters 8(7): 837-42 (1998).
	BZ3	Kawakami, et al., XP 002201344 – AN 1999 – 2290406, "Corneal neovascularization inhibitor useful e.g. with corneal grafts," Abstract WO 9913909 (1999).
	CA3	Kishnani, et al., <i>Identification and Characterization of Human Tissue Inhibitor of Metalloproteinase-3 and Detection of Three Additional Metalloproteinase Inhibitor Activities in Extracellular Matrix</i> , Matrix Biology 14(6): 479-88 (1995).
	CB3	Klement, et al., <i>Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity</i> , J. Clin. Invest. 105(8): R15-24 (2000).
	CC3	Klein, et al., <i>The Wisconsin Epidemiologic Study of Diabetic Retinopathy</i> , Arch. Ophth. 112: 1217-1228 (1994).
	CD3	Lyons-Giordano, et al., <i>The Effect of Heparin on Fibronectin and Thrombospondin Synthesis and mRNA Levels in Cultured Human Endothelial Cells</i> , Exp. Cell Research 186(1): 39-46 (1990).
	CE3	Melchiori, et al., <i>Inhibition of Tumor Cell Invasion of a Highly Conserved Peptide Sequence from the Matrix Metalloproteinase Enzyme Prosegment</i> , Cancer Research 52(8): 2353-56 (1992).
	CF3	Murphy, A.N., et al., <i>Tissue Inhibitor of Metalloproteinases-2 Inhibits bFGF-Induced Human Microvascular Endothelial Cell Proliferation</i> , Journal of Cell Physiology 157(2): 351-58 (1993).
	CG3	Murphy, G., et al., <i>The N-Terminal Domain of Tissue Inhibitor of Metalloproteinases Retains Metalloproteinase Inhibitory Activity</i> , Biochemistry 30(33): 8097-102 (1991).
	CH3	Odake, et al., <i>Inhibition of Matrix Metalloproteinases By Peptidyl Hydroxamic Acids</i> , Biochem Biophys Res Commun 199(3): 1442-46 (1994).
	CI3	Ostendorf, et al., <i>VEGF₁₆₅ mediates glomerular endothelial repair</i> ,

EXAMINER



DATE CONSIDERED

2/25/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO.		APPLICATION NO.		<div style="font-size: 2em; font-weight: bold; transform: rotate(-5deg);">RECEIVED</div> <div style="font-size: 1.5em; font-weight: bold; transform: rotate(-5deg);">SEP 27 2002</div> <div style="font-size: 1.5em; font-weight: bold; transform: rotate(-5deg);">TECH CENTER 1600/2900</div>	
				13587.286		09/523,102			
				APPLICANTS					
				SI, <i>et al.</i>					
				FILING DATE		GROUP			
				March 10, 2000					
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
		CJ4							
		CK4							
		CL4							
FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
		CM4					Yes No		
		CN4							
		CO4							
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)									
4	CP4		Pikul, <i>et al.</i> , <i>Design and Synthesis of Phosphinamide-Based Hydroxamic Acids as Inhibitors of Matrix Metalloproteinases</i> , Journal of Medical Chemistry 42(1): 87-94 (1999).						
8	CQ4		Possati, <i>et al.</i> , Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in Kaposi's sarcoma-like murine model, Clin. Exp. Metastasis 17(7): 575-82 (1999).						
8	CR4		Shapiro, <i>et al.</i> , <i>Dexamethasone Selectively Modulates Basal and Lipopolysaccharide-Induced Metalloproteinase and Tissue Inhibitor of Metalloproteinase Production By Human Alveolar Macrophages</i> , Journal of Immunology 146(8): 2724-29.						
8	CS4		Siemeister, <i>et al.</i> , An antagonistic vascular endothelial growth factor (VEGF): variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells, Proceedings of the National Academy of Sciences U.S.A. 95: 4625-29 (1998).						
8	CT4		Stack, <i>et al.</i> , <i>Application of N-Carboxyalkyl Peptides to the Inhibition and Affinity Purification of the Porcine Matrix Metalloproteinases Collagenase, Gelatinase, and Stromelysin</i> , Arch. Biochem. Biophys. 287(2): 240-49 (1991).						
8	CU4		Steinman, <i>et al.</i> , <i>The Design, Synthesis, and Structure-Activity Relationships of a Series of Macrocyclic MMP Inhibitors</i> , Bioorganic Medical Chemistry Letters 8(16): 21087-92 (1998).						
8	CV4		Sunamura, <i>et al.</i> , <i>The Antiangiogenesis Effect of Interleukin 12 During Early Growth of Human Pancreatic Cancer in SCID Mice</i> , Pancreas 20(3): 227-33 (2000).						
8	CW4		Wallon, <i>et al.</i> , <i>Polyamine-Dependent Expression of the Matrix Metalloproteinase Matrilysin in a Human Colon Cancer-Derived Cell Line</i> , Mol. Carcinog. 11(3): 138-44 (1994).						
8	CX4		Wentworth, <i>et al.</i> , <i>Effect of a Metalloproteinase Inhibitor on Established Corneal Ulcers After an Alkali Burn</i> , Invest. Ophthalmol. Vis. Sci. 33(7): 2174-79 (1992).						
8	CY4		Willis, <i>et al.</i> , <i>Liposome-Anchored Vascular Endothelial Growth Factor Aptamers</i> , Bioconjug. Chem. 9(5): 573-82 (1998).						
8	CZ4		Zhang, <i>et al.</i> , <i>Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d)</i> , Proceedings of the National Academy of Sciences U.S.A. 91: 8447-51 (1994).						
	DA4								
	DB4								
EXAMINER					DATE CONSIDERED				
					<div style="font-size: 1.5em; font-weight: bold;">2/25/03</div>				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									